Morgan Stanley cuts target for BioNTech stock to USD 114.00

Published on 10/08/2026 at 11:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue fell to EUR 105.60 million from EUR 260.80 million. BioNTech stock costs EUR 84.33 on October 8, 2026 after EUR 85.03.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

BioNTech SE (ISIN US09075V1026) was trading at EUR 84.33 at Lang & Schwarz on October 8, 2026 at 11:35 a.m. CEST, with a minus 0.82 percent change versus the EUR 85.03 prior close. On October 7, 2026, Morgan Stanley analyst Terence Flynn lowered the firm's BioNTech target from USD 115.00 to USD 114.00 while keeping an Overweight rating, as Markets Insider reported.

Target cut points to caution

The change was modest in size, but its timing matters because Morgan Stanley adjusted its model ahead of BioNTech's third-quarter earnings. The report cited IQVIA trends and intra-quarter updates, giving investors a concrete reason to focus on commercial demand as the company shifts toward oncology.

The new USD 114.00 target remains USD 29.67 above the USD 84.33 Lang & Schwarz price, but the two figures belong to different currencies and are not a direct return calculation. The more useful signal is the direction of the estimate: Morgan Stanley kept its Overweight view while trimming the target by USD 1.00, or 0.87 percent, from USD 115.00.

Second-quarter revenue contracted

BioNTech's second-quarter 2026 revenue fell to EUR 105.60 million from EUR 260.80 million in the year-earlier quarter, a 59.50 percent decline, according to Finanztrends. The same report said BioNTech posted a EUR 820.80 million net loss for the quarter and reduced its 2026 revenue outlook to EUR 1.60 billion to EUR 1.90 billion from EUR 2.00 billion to EUR 2.30 billion.

The comparison explains why an oncology pipeline catalyst must compete with near-term vaccine revenue pressure. BioNTech's investor page describes the business as a biopharmaceutical company focused on cancer therapies and other serious diseases, with late-stage programs spanning immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies.

Nasdaq range frames the quote

On the Nasdaq, BNTX was last quoted at USD 95.25 on October 7, 2026 at 4:00 p.m. ET, according to the finance quote, with a USD 79.52 to USD 124.00 52-week range and a market capitalization of USD 23.9 billion. Those US-dollar figures provide exchange context, while the euro quote remains the reference for German-market readers.

BioNTech stock was trading at EUR 84.33 at Lang & Schwarz on October 8, 2026 at 11:35 a.m. CEST, versus the EUR 85.03 prior close and with a minus 0.82 percent change. The further course of trading is shown by the continuously updated real-time quote of BioNTech stock.